BofA Lowers Alnylam Price Target to $460, Keeps Buy Rating as 2026 Catalysts Line Up
BofA Securities reduced its price target for Alnylam Pharmaceuticals (ALNY) to $460 from $462 while retaining a Buy rating. The bank highlighted a slate of clinical milestones and potential regulatory filings in 2026, even as Alnylam's most recent quarterly results produced an earnings surprise but missed revenue expectations. The stock is trading …